Doreen Cassarino
Nurse Practitioner · Naples, FLNPI 1245266493
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 27.9% of the total. Reporting peaked in 2021 at $11,469 and has fallen 51.5% since, to $5,557 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 955 payments — averaging $42.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$11K
- AstraZeneca$11K
- Novo Nordisk$4K
- Bayer$4K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- plus $9K from 45 others
What the payments were for
- Consulting fees$2,0095%
- Speaking & faculty fees$17,85244%
- Travel & lodging$2,6066%
- Food & beverage$18,15545%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$9,872
- SOLIQUA 100/33$6,945
- Kerendia$2,356
- Lynkuet$928
- TOUJEO$339
- KRYSTEXXA$125
- Ozempic$125
- FREESTYLE LIBRE 3$112
- FreeStyle Libre 2$109
How this compares
$40,728 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 390 | $535,494 |
| OzempicSemaglutide | 394 | $526,404 |
| MounjaroTirzepatide | 239 | $275,308 |
| TrulicityDulaglutide | 126 | $171,786 |
| KerendiaFinerenone | 113 | $132,585 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $102,057 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 87 | $100,727 |
| JanuviaSitagliptin Phosphate | 83 | $98,755 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $65,277 |
| EliquisApixaban | 56 | $61,904 |
| Tresiba Flextouch U-100Insulin Degludec | 83 | $57,285 |
| ProliaDenosumab | 32 | $56,284 |
| Repatha SureclickEvolocumab | 47 | $49,775 |
| RybelsusSemaglutide | 20 | $49,224 |
| FarxigaDapagliflozin Propanediol | 40 | $42,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy, Novolog | $3,813 | $615,827451 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $1,353 | $581,571434 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,245 | $454,414383 claims |
| BayerKerendia | $3,545 | $132,585113 claims |
| MerckJanuvia, Janumet | $283 | $130,534113 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $11,372 | $100,72787 claims |
| PfizerEliquis | $597 | $61,90456 claims |
| AmgenProlia | $1,130 | $56,28432 claims |
| Johnson & JohnsonXarelto, Invokana | $307 | $43,71841 claims |
| AstraZenecaFarxiga | $10,876 | $42,63440 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $201 | $29,25533 claims |
| NovartisEntresto | $360 | $17,53716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Naples
- Stephanie SimmermanNaples$283K
- Tara McGaheyNaples$21K
- Stephanie ChandlerNaples$20K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.